ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: PO0559

Role of Adipose Tissue-Derived Mesenchymal Stem Cells in CKD: A Phase 1 Study Assessing Safety and Clinical Feasibility

Session Information

Category: CKD (Non-Dialysis)

  • 2102 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Author

  • Cai-Mei, Zheng, Taipei Medical University College of Medicine, Taipei, Taiwan
Background

Chronic kidney disease (CKD) is a most common progressive disorder associated with high mortality and huge socio-economic burden globally. We hypothesize that allogeneic adipose tissue mesenchymal stromal cells (hASCs) are renotropic and may retard CKD progression through anti-apoptotic, anti-fibrotic, and anti-inflammatory effects. In this study, we will assess the safety and tolerability of a hASCs infusion in CKD patients with various underlying etiologies.

Methods

We performed a single-arm phase I clinical trial with a 6-month follow-up. This study enrolled 12 eligible CKD patients with an estimated glomerular filtration rate (eGFR) of 15-44 mL/min/1.73m2 (mL/min). Patients were allocated to receive low, moderate, or high dose of allogeneic cultured hASCs infusion. We investigated the safety issues and kidney function during the follow-up visits.

Results

There was no patient lost to follow-up. We observed two treatment related adverse events (AE) in high dose group. One subject experienced grade 1 slow speech immediately after hASCs infusion, which was resolved on the next day and completely normal afterwards. The AE was considered possibly related to study treatment and met dose-limiting toxicity (DLT). Another subject experienced grade 1 bradyphrenia after the infusion, and the situation was resolved during the following 9 days, however, this AE was not considered as DLT. One SAE was reported in moderate dose group, who was hospitalized for persistent heavy proteinuria, and later proved as diabetic nephropathy stage 4 by renal biopsy. No significant reduction in eGFR was noted among all treated patients, and specifically an improvement in eGFR was noted among those with baseline eGFR>30mL/min. No significant reduction in proteinuria was noted.

Conclusion

This trial demonstrated the safety and tolerability of allogenic hASCs infusion in stages 3b and 4 CKD patients. Patients with reserved renal function (e.g. eGFR>30mL/min) could be more beneficial from hASCs compared to those without. hASCs efficacy and dosing interval in various CKD stages should be investigated in future randomized placebo-controlled trial among various CKD population.